1. Advances in the treatment of ANCA-associated vasculitis.
作者: Giorgio Trivioli.;Marta Casal Moura.;Andreas Kronbichler.;Rona M Smith.;Benjamin Terrier.;Stephen McAdoo.;Rachel B Jones.;Peter A Merkel.;David R W Jayne.
来源: Nat Rev Rheumatol. 2025年
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) consists of a group of small-vessel vasculitides that often present with organ-threatening or life-threatening manifestations. Current immunosuppressive treatments have improved survival and rates of remission, but are not curative, have frequent toxicities, and do not effectively prevent relapse. Clinical trials have established the role of rituximab, an anti-CD20 B cell-depleting monoclonal antibody, in both the remission-induction and maintenance phases of the disease and demonstrated that glucocorticoid doses can be substantially reduced from historical dosing levels without affecting treatment efficacy. Therapies that have the potential to be more effective and safer have become available or are under investigation. Avacopan, an oral C5a receptor antagonist, was approved as an adjunctive treatment for AAV and use of this drug in combination with rituximab or cyclophosphamide and markedly reduced glucocorticoid dosing demonstrated superior efficacy and potentially greater kidney recovery than prior standard of care. Other agents under study for treatment of AAV include next-generation anti-CD20 monoclonal antibodies, anti-CD19 chimeric antigen receptor T cells, novel complement inhibitors and agents that can target fibrosis. Alongside traditional randomized controlled trials with clinical endpoints, experimental medicine studies are focusing on mechanistic endpoints and disease biomarkers. This Review discusses current treatments and the advances in the management of AAV.
2. Trends in the prevalence of autoimmune diseases during pregnancy in the UK, 2000-21: a retrospective cohort study.
作者: Megha Singh.;Katherine Phillips.;Jingya Wang.;Anuradhaa Subramanian.;Kelly-Ann Eastwood.;Krishnarajah Nirantharakumar.;Francesca L Crowe.
来源: Lancet Rheumatol. 2025年
Autoimmune diseases are increasingly prevalent worldwide and disproportionately affect women of reproductive age, including during pregnancy. Given the association between autoimmune diseases, comorbidities, and risk factors for adverse pregnancy outcomes, we aimed to estimate the burden of autoimmune disease in pregnancy.
4. SPAG11B, a potential biomarker for rheumatoid arthritis: a two-sample bidirectional Mendelian randomization analysis.
The incidence of rheumatoid arthritis (RA) is rising. However, its pathogenesis has not been fully understood, and the current therapeutic regimens are still limited. The aim of this study was to investigate the causal effect of plasma proteins on RA using Mendelian randomization (MR) analysis.
6. Long-term effectiveness of non-surgical interventions for chronic low back pain: a systematic review and meta-analysis.
作者: Hazel J Jenkins.;Leticia Corrêa.;Benjamin T Brown.;Giovanni E Ferreira.;Casper Nim.;Sasha L Aspinall.;Deborah Wareham.;Junghyun Choi.;Christopher G Maher.;Mark J Hancock.
来源: Lancet Rheumatol. 2025年
Chronic low back pain is a long-term recurrent condition. Interventions with sustained benefits are needed to reduce the associated personal and societal burden. We aimed to assess the long-term effectiveness of non-surgical interventions for reducing pain intensity and disability in adults with chronic low back pain.
7. Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.
作者: Michel Moutschen.;Cécile Boulanger.;Joke Dehoorne.;Rik Joos.;Florence Roufosse.;Vito Sabato.;Jeroen van der Hilst.;Eleonore Maury.;Hilde Rabijns.;Marijn Witterzeel.;Carine Wouters.
来源: BMC Rheumatol. 2025年9卷1期64页
Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain insights into canakinumab use and treatment patterns for these diseases in Belgium.
8. Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus.
作者: Yves Renaudineau.;Emmanuel Treiner.;Fabrice Herin.;Stanislas Faguer.;Gregory Pugnet.;Laurent Sailler.
来源: Rheumatology (Oxford). 2025年
To investigate the ex vivo IFN-γ release assay (IGRA) as a biomarker of SLE activity and disease outcome.
9. An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in systemic sclerosis-related Raynaud's phenomenon.
作者: Ariane L Herrick.;Andrea Murray.;Graham Dinsdale.;Joanne Manning.;Chukwuma Chukwu.;Marcia Alvarez Fernandez.;Ulrika Axling.;James R Seibold.;Fredrik Tiberg.
来源: Rheumatology (Oxford). 2025年
Our aim was to explore the effect of a single subcutaneous dose of CAM2043, a novel extended-release subcutaneous formulation of treprostinil, on finger temperature in patients with systemic sclerosis (SSc)-related Raynaud's phenomenon (RP).
10. Ankylosed posterior spinal structures: the catalyst for syndesmophytes growth and impaired spinal mobility in axial spondyloarthritis.
作者: Simin Liao.;Jian Zhu.;Liuquan Cheng.;Zheng Zhao.;Gui Luo.;Chuan Song.;Jiaxin Zhang.;Feng Huang.
来源: Rheumatology (Oxford). 2025年
To identify risk factors for spinal structural progression and determine the most significant impact on syndesmophytes growth and impaired spinal mobility in axSpA.
12. Immunoadsorption as a novel therapy for refractory idiopathic inflammatory myopathies-a retrospective observational study.
作者: Kastriot Kastrati.;Thomas Karonitsch.;Hanien Rajab.;Roman Reindl-Schwaighofer.;Farsad Eskandary.;Sahra Pajenda.;Daniel Mrak.;Peter Maximilian Heil.;Hans Peter Kiener.;Michael Bonelli.;Kurt Derfler.;Daniel Aletaha.;Josef S Smolen.;Helga Radner.
来源: Rheumatology (Oxford). 2025年
Idiopathic inflammatory myopathies (IIM) are autoimmune disorders characterised by muscle inflammation, high creatine kinase (CK) levels, and disability. Despite immunomodulating therapies, patients often experience progressive disease, resulting in refractory conditions or dependence on glucocorticoids (GC). This study addresses the efficacy and safety of immunoadsorption (IAS) in refractory IIM.
16. Real-world evidence of biological treatments in rheumatoid arthritis and spondyloarthritis in Morocco: results of the RBSMR registry.
作者: Najlae El Ouardi.;Ihsane Hmamouchi.;Redouane Abouqal.;Fadoua Allali.;Rachid Bahiri.;Imane El Bouchti.;Imad Ghozlani.;Hasna Hassikou.;Linda Ichchou.;Saadia Janani.;Taoufik Harzy.;Radouane Niamane.;Ahmed Bezza.;Abdellah El Maghraoui.
来源: BMC Rheumatol. 2025年9卷1期62页
Regional variability in the effectiveness and safety of biologic therapies for rheumatoid arthritis (RA) and spondyloarthritis (SpA) underscores the need for comprehensive assessment. The aim of this study was to provide real-world evidence of the effectiveness and the safety of biologic for RA, SpA including psoriatic arthritis, in the daily clinical practice.
17. Does osteoarthritis physiotherapy research in South Korea align with the National Institute for Health and Care Excellence guidelines: a systematic review of English and Korean literature.
Osteoarthritis (OA) is a leading cause of lower limb disability worldwide, imposing significant socioeconomic and personal burden. Thus, many internationally recognised organisations have developed management guidelines for this condition. Among these, the National Institute for Health and Care Excellence (NICE) recommends four first-line approaches to osteoarthritis management: education, exercise, self-management, and weight management. Despite the development of guidelines, adherence to OA management recommendations appears to be suboptimal internationally, and little is known about guideline adherence in South Korea. This study aimed to explore whether research-based physiotherapy interventions for OA in South Korea align with the NICE guidelines.
18. Risk of heart disease in neonates born to mothers with primary Sjögren's syndrome: a multicenter retrospective study.
作者: Yingbo Zhou.;Meilin Shao.;Yinzhao Jin.;Zhen Tan.;Li Wang.;Yan Ma.;Nan Xiang.;Xiang Yuan.;Bin Wang.;Jie Meng.;Xiangliang Xie.;Mingtao Zhou.;Yunmin Wang.;Lin Liu.;Xiaomei Li.
来源: Rheumatology (Oxford). 2025年
The impact of primary Sjögren's syndrome (pSS) on adverse pregnancy outcomes remains a debated issue. Research suggests that newborns of mothers with pSS may be at a higher risk of developing heart conditions. This study aimed to examine the relationship between maternal pSS and the risk of cardiac disorders in neonates.
19. Clinical-imaging characteristics and management of anti-JO-1 and non-JO-1 anti-synthetase syndrome-associated interstitial lung disease.
作者: Wanqing Zhou.;Ranxun Chen.;Xi Chen.;Weiwei Xie.;Qingqing Xu.;Yin Liu.;Lulu Chen.;Bi Chen.;Jinghong Dai.
来源: Rheumatology (Oxford). 2025年
Given a substantial proportion of patients with ASS-ILD (anti-synthetase syndrome-associated interstitial lung disease) develop progressive pulmonary fibrosis (PPF), we aimed to investigate the clinical-radiographic characteristics and treatment in patients with or without anti-Jo-1 antibody.
20. Diffuse idiopathic skeletal hyperostosis as a marker for incident diabetes mellitus in cardiovascular disease patients.
作者: Netanja I Harlianto.;Wouter Foppen.;Firdaus A A Mohamed Hoesein.;Marjolein E Hol.;Jorrit-Jan Verlaan.;Pim A de Jong.;Jan Westerink.; .
来源: Rheumatology (Oxford). 2025年
Diffuse idiopathic skeletal hyperostosis (DISH) is a common incidental finding in medical imaging characterized by continuous vertebral ossification, which is associated with prevalent type 2 diabetes mellitus (T2DM). We hypothesized that incidental screen-detected DISH may be an actionable marker for incident diabetes screening and aimed to assess the absolute incidence rate (ratio) for T2DM in cardiovascular patients with and without DISH.
|